Archive for May, 2012

In-Pipe Technology Announces Webinar Series on Municipal Wastewater…

In-Pipe Technology will host a webinar series to discuss how In-Pipe’s green sewer collection system treatment can prevent wastewater overflows related to fats, oil, and grease.(PRWeb May 31, 2012)Read the full story at http://www.prweb.com/releas…


Bed Bug Elimination: BedBugBully Brings Out Pesticide-Exempt Bed Bug…

Online company BedBugBully.com offered a new product for a safe and effective bed bug elimination. It released a pesticide-exempt bed bug spray made from natural ingredients.(PRWeb May 31, 2012)Read the full story at http://www.prweb.com/releases/20…


Drug Patent Expirations for May 15 2012

If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations

<TD align=right–>
ADVERTISE
HERE
Who are the leading pharmaceutical patent challengers? A report on<br />
Paragraph IV challenges<!–/td>

This
newsletter is a free service of DrugPatentWatch

DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents

Simple flat-rate
database subscription plans

Ultimate
Plan
Premium Plan Basic Plan
One year $1,995 Subscribe $1,795 Subscribe $1,095 Subscribe
One month $525 Subscribe $425 Subscribe $325 Subscribe
48 hours $95 Subscribe $75 Subscribe
Plan
comparison
    Site
tour
    Contact





Drug Patent Expirations for May 15 2012

Tradename Applicant Generic Name Patent Number Patent Expiration
COMBIVIR Viiv
Hlthcare
lamivudine; zidovudine 5,859,021 May 15,
2012

*Drugs may be covered by multiple
patents or regulatory protections. See the DrugPatentWatch
database for complete details.







DrugPatentWatch Fills Your Competitive Intelligence
Needs

Subscribers have
access to valuable datasets, including:
  • Clinical trial information
  • International patent families
  • International patent priority and PCT
    information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data
    export
  • More…
See the Database
Preview
and Plan
Comparison
. Contact Us with any
questions.





The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.


Continue reading

Drug Patent Expirations for May 17 2012

If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations

Journal of Commercial Biotechnology
ADVERTISE
HERE

This
newsletter is a free service of DrugPatentWatch

DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents

Simple flat-rate
database subscription plans

Ultimate
Plan
Premium Plan Basic Plan
One year $1,995 Subscribe $1,795 Subscribe $1,095 Subscribe
One month $525 Subscribe $425 Subscribe $325 Subscribe
48 hours $95 Subscribe $75 Subscribe
Plan
comparison
    Site
tour
    Contact





Drug Patent Expirations for May 17 2012

Tradename Applicant Generic Name Patent Number Patent Expiration
PLAVIX Sanofi Aventis
Us
clopidogrel bisulfate 4,847,265*PED May
17, 2012

*Drugs may be covered by multiple
patents or regulatory protections. See the DrugPatentWatch
database for complete details.







DrugPatentWatch Fills Your Competitive Intelligence
Needs

Subscribers have
access to valuable datasets, including:
  • Clinical trial information
  • International patent families
  • International patent priority and PCT
    information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data
    export
  • More…
See the Database
Preview
and Plan
Comparison
. Contact Us with any
questions.





The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.

Share this:


Continue reading

Drug Patent Expirations for May 22 2012

If your reader cannot render the information below, go to
http://www.DrugPatentWatch.com/innovation to see the latest expirations

<TD align=right–>
ADVERTISE
HERE
FDA Orange Book archives from 2005 to<br />
present<!–/td>

This
newsletter is a free service of DrugPatentWatch

DrugPatentWatch offers comprehensive details on FDA approved drugs,
developers, and their patents

Simple flat-rate
database subscription plans

Ultimate
Plan
Premium Plan Basic Plan
One year $1,995 Subscribe $1,795 Subscribe $1,095 Subscribe
One month $525 Subscribe $425 Subscribe $325 Subscribe
48 hours $95 Subscribe $75 Subscribe
Plan
comparison
    Site
tour
    Contact





Drug Patent Expirations for May 22 2012

Tradename Applicant Generic Name Patent Number Patent Expiration
ACTONEL Warner
Chilcott
risedronate sodium 6,096,342*PED May
22, 2012
VIRAMUNE Boehringer
Ingelheim
nevirapine 5,366,972*PED May
22, 2012
VIRAMUNE
XR
Boehringer Ingelheim nevirapine 5,366,972*PED May
22, 2012

*Drugs may be covered by multiple
patents or regulatory protections. See the DrugPatentWatch
database for complete details.







DrugPatentWatch Fills Your Competitive Intelligence
Needs

Subscribers have
access to valuable datasets, including:
  • Clinical trial information
  • International patent families
  • International patent priority and PCT
    information
  • Patent maintenance
  • Full-text patent downloads
  • Sales data (top 200 drugs)
  • Paragraph IV challenges
  • Tentative approvals
  • Dynamic search capabilities with data
    export
  • More…
See the Database
Preview
and Plan
Comparison
. Contact Us with any
questions.





The above list
does not discriminate between dominant and non-dominant patents. Drugs
listed above may be protected by additional patents and other regulatory
protections. See the DrugPatentWatch
database for complete details

DISCLAIMER:
Although great care is taken in the proper and correct provision of this
service, thinkBiotech LLC does not accept any responsibility for possible
consequences of errors or omissions in the provided information. There is
no warranty that the information contained herein is error free. Users of
this service are advised to seek professional advice and independent
confirmation before acting on any of the provided information. thinkBiotech
LLC reserves the right to amend, extend or withdraw any part or all of the
offered service without notice.
All trademarks and applicant names
are the property of their respective owners or
licensors.


Continue reading

NeuroTracker Validation at IMG Performance Institute

Prompted by its use at the 2012 NFL Combine, the CogniSens Athletics NeuroTracker is now a central part of the IMG Vision Training Program.(PRWeb May 30, 2012)Read the full story at http://www.prweb.com/releases/2012/5/prweb9556820.htm


Continue reading

50% off DrugPatentWatch reports for a limited time

I am running a special discount at DrugPatentWatch through the end of June: 50% off all reports through June 30 2012. These pharmaceutical industry reports are produced by data-mining the DrugPatentWatch Database, and provide detailed information on FDA-approved pharmaceutical drugs. Please contact me with any special data needs beyond the existing report catalog. Global Drug Patent […]


Continue reading

Ion Channel Analysis Platform Launches at ELA 2012

Genedata Screener for Ion Channel Screening supports the latest lab technologies while reducing data analysis times by 95%(PRWeb May 30, 2012)Read the full story at http://www.prweb.com/releases/Ion_channel_screening/Genedata_Screener/prweb9556074.htm


Continue reading

Selexis SA to Partner and Exhibit at BIO 2012 in Boston MA

Selexis to Meet with Companies Interested in Mammalian Cell Line Development, Lead Identification for Therapeutic Drug Development and Solutions for Difficult-to-Express Proteins(PRWeb May 30, 2012)Read the full story at http://www.prweb.com/release…


Continue reading

BioPharm Systems Unveils Oracle Health Sciences Empirica Topics…

New drug safety signal detection and management software application helps life sciences companies track and manage information related to potential drug safety and pharmacovigilance signals.(PRWeb May 30, 2012)Read the full story at http://www.prwe…


Continue reading